Prurigo Nodularis (Investigational Adjunct)
Investigational adjunct for refractory prurigo nodularis; potent topical/intralesional steroids, gabapentinoids, and dupilumab (FDA-approved 2022) remain evidence-based.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for prurigo nodularis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- What evidence exists?
- Tier C (investigational). No clinical study of leech therapy for prurigo nodularis was identified, so its effect is unknown. Evidence-based first-line management is high-potency topical corticosteroid under occlusion, intralesional triamcinolone, topical tacrolimus or cryotherapy for limited disease, and for moderate-to-severe disease dupilumab (FDA-approved 2022 for prurigo nodularis), nemolizumab, or other systemic options including gabapentinoids and antidepressants for itch control.
- Main risks
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Small Y-shaped bite marks or skin colour changes at the bite sites, which usually fade over weeks to months
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Itch worsening immediately after leech sessions
- Aggravation of nodules by additional cutaneous inflammation
- Triggering scratch-itch cycle relapse
- Who should not consider this
- Patients eligible for dupilumab who have not been offered it (FDA-approved for moderate-to-severe PN)
- Patients without workup for underlying itch causes (renal disease, cholestasis, hematologic, atopic dermatitis)
- Patients with poorly controlled atopic dermatitis or psoriasis driving the itch
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran or heparin (daily aspirin alone is not a contraindication: tell your doctor, who starts with fewer leeches)
- People with hemophilia or any other inherited bleeding disorder
- Patients with anemia
- People with an active infection at the planned application site
- What to ask your clinician
- Has dupilumab — the FDA-approved biologic for PN — been considered or tried?
- Have I been worked up for systemic causes of itch (renal, liver, hematologic)?
- Have I tried gabapentin or an antidepressant for the itch component?
- What is the published evidence base for leeches in PN?
- What is the risk that bites worsen itch or trigger more nodule formation?
- How will treatment success be measured?
- When to seek urgent care
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Spreading infection at nodule sites with fever
- Sudden uncontrolled itch with new systemic symptoms (jaundice, weight loss, lymphadenopathy)
What this does NOT mean
- It does not mean leech therapy is FDA-cleared for prurigo nodularis — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace dupilumab, which IS FDA-approved for moderate-to-severe PN.
- It does not address the scratch-itch cycle that perpetuates nodules.
- It does not exclude or treat systemic causes of itch.
- It does not have controlled-trial evidence in prurigo nodularis; no clinical study of leech therapy for it was identified.
Safety cross-references
Clinical Profile
- Category
- Dermatological
- ICD-10
- L28.1, L29.8
- Safety tier
- Medium
Evidence Summary
Prurigo nodularis is a chronic inflammatory dermatosis with hyperkeratotic, intensely pruritic nodules in the itch-scratch cycle. Evidence-based management includes potent topical or intralesional corticosteroids, calcineurin inhibitors, topical capsaicin, oral gabapentinoids or low-dose naltrexone for itch, phototherapy, and dupilumab (FDA-approved for moderate-to-severe prurigo nodularis in 2022). Nemolizumab (anti-IL-31RA) has positive phase III data. No clinical study or case report of hirudotherapy for prurigo nodularis was identified in PubMed, Europe PMC, Crossref or Russian- and German-language sources as of October 2026. The nearest leech data are small open-label eczema studies (Shankar 2014, 27 patients; Ulla P 2025, 20 patients), which did not include prurigo nodularis. Lesions are often on extensor surfaces in elderly patients with comorbid systemic disease.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Excoriated, infected, or actively oozing nodule
- Underlying systemic itch cause not worked up (uremia, cholestasis, lymphoma)
- Dupilumab eligible and accessible (use evidence-based therapy)
- HIV or other immunocompromise where superinfection risk is high
Related Conditions
Atopic Eczema (Localized Refractory)
Investigational use for localized refractory eczema; evidence is limited to a few small studies without placebo or standard-care controls.
Cutaneous Lichen Planus (Localized)
Investigational use for localized cutaneous lichen planus refractory to topical corticosteroid; very limited case-report evidence.
Plaque Psoriasis (Localized)
Investigational adjunct, not a primary treatment; a few small, mostly uncontrolled studies report lower PASI scores.
Livedo Reticularis
Investigational use for primary livedo reticularis; no clinical study was identified. Secondary causes (lupus, APLAS) require rheumatology referral.